This will be a familiar dialog not only to investors but also to those in biopharma (who perhaps should be thought of as investors as well), as they continuously need to decide whether to go for a risky potential blockbuster or more of a sure-thing that ostensibly may be associated with a smaller market.
For example, I may be very impulsive and make decisions too quickly, this may discourage others from starting dialog about why other options upon further look may make more sense in the long or short term.